JAMA Neurology : Gefurulimab and Generalized Myasthenia Gravis

Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD.

Related Content:

• Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis
• Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy